Mouse models of prostate cancer: picking the best model for the question

被引:87
作者
Grabowska, Magdalena M. [1 ]
DeGraff, David J. [1 ]
Yu, Xiuping [1 ]
Jin, Ren Jie [1 ]
Chen, Zhenbang [2 ]
Borowsky, Alexander D. [3 ]
Matusik, Robert J. [1 ]
机构
[1] Vanderbilt Univ, Nashville, TN 37235 USA
[2] Meharry Med Coll, Nashville, TN 37208 USA
[3] Univ Calif Davis, Davis, CA 95616 USA
关键词
Mouse models; Prostate cancer; TRAMP; LADY; PTEN; Myc; SMALL-CELL CARCINOMA; ANDROGEN RECEPTOR; INTRAEPITHELIAL NEOPLASIA; GENE-EXPRESSION; PTEN LOSS; MOLECULAR CHARACTERIZATION; MALIGNANT-TRANSFORMATION; NEUROENDOCRINE CARCINOMA; CONDITIONAL EXPRESSION; HISTOLOGICAL VARIANTS;
D O I
10.1007/s10555-013-9487-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?.
引用
收藏
页码:377 / 397
页数:21
相关论文
共 163 条
[51]   THE RAT PROBASIN GENE PROMOTER DIRECTS HORMONALLY AND DEVELOPMENTALLY-REGULATED EXPRESSION OF A HETEROLOGOUS GENE SPECIFICALLY TO THE PROSTATE IN TRANSGENIC MICE [J].
GREENBERG, NM ;
DEMAYO, FJ ;
SHEPPARD, PC ;
BARRIOS, R ;
LEBOVITZ, R ;
FINEGOLD, M ;
ANGELOPOULOU, R ;
DODD, JG ;
DUCKWORTH, ML ;
ROSEN, JM ;
MATUSIK, RJ .
MOLECULAR ENDOCRINOLOGY, 1994, 8 (02) :230-239
[52]  
Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO
[53]  
2-1
[54]   Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis [J].
Gurel, Bora ;
Iwata, Tsuyoshi ;
Koh, Cheryl M. ;
Jenkins, Robert B. ;
Lan, Fusheng ;
Van Dang, Chi ;
Hicks, Jessica L. ;
Morgan, James ;
Cornish, Toby C. ;
Sutcliffe, Siobhan ;
Isaacs, William B. ;
Luo, Jun ;
De Marzo, Angelo M. .
MODERN PATHOLOGY, 2008, 21 (09) :1156-1167
[55]   Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer [J].
Han, GZ ;
Foster, BA ;
Mistry, S ;
Buchanan, G ;
Harris, JM ;
Tilley, WD ;
Greenberg, NM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) :11204-11213
[56]   Sarcomatoid carcinoma of the prostate: A study of 42 cases [J].
Hansel, Donna E. ;
Epstein, Jonathan I. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (10) :1316-1321
[57]  
Hayward SW, 2001, CANCER RES, V61, P8135
[58]   Modeling Prostate Cancer in Mice: Limitations and Opportunities [J].
Hensley, Patrick J. ;
Kyprianou, Natasha .
JOURNAL OF ANDROLOGY, 2012, 33 (02) :133-144
[59]   Metastatic patterns in adenocarcinoma [J].
Hess, KR ;
Varadhachary, GR ;
Taylor, SH ;
Wei, W ;
Raber, MN ;
Lenzi, R ;
Abbruzzese, JL .
CANCER, 2006, 106 (07) :1624-1633
[60]   Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model [J].
Hill, R ;
Song, YR ;
Cardiff, RD ;
Van Dyke, T .
CANCER RESEARCH, 2005, 65 (22) :10243-10254